Fostamatinib (Tavlesse®) accepted for restricted use within NHS Scotland for treatment of chronic immune thrombocytopenia (ITP) in adults

Restricted to treatment of patients with severe symptomatic ITP or with a high risk of bleeding who have not had a suitable response to other therapies, including a thrombopoietin receptor‐agonist (TPO-RA), or where use of a TPO-RA is not appropriate.

Source:

Scottish Medicines Consortium